Research progress on prostate cancer gene mutations based on whole-exome sequencing technology
10.3969/j.issn.1009-8291.2025.05.013
- VernacularTitle:基于全外显子组测序技术的前列腺癌基因突变研究进展
- Author:
Kaige ZHANG
1
;
Ning TAO
2
;
Hengqing AN
1
Author Information
1. First Affiliated Hospital, Urumqi 830000, China
2. School of Public Health, Xinjiang Medical University, Urumqi 830000, China
- Publication Type:Journal Article
- Keywords:
prostate cancer;
whole-exon sequencing;
second-generation sequencing;
gene mutation;
targeted therapy
- From:
Journal of Modern Urology
2025;30(5):442-447
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer (PCa) is one of the most common cancer among men worldwide.With the continuous development of genomics technology，a large number of studies have confirmed that different types of gene mutations affect the clinical manifestations，progression and prognosis of PCa.Tumor genomics research can go deep into the gene level to explore the causes of PCa，explore possible biomarkers，and identify potential therapeutic targets.This paper discusses the development and application of whole-exome sequencing (WES) in prostate cancer，including DNA damage repair (DDR) related gene mutations，homologous recombination repair (HRR) key gene mutations，other HRR related gene mutations，mismatch repair related gene mutations and other gene mutations，differences in PCa gene mutations between different races，and differences in localized PCa and metastatic PCa gene mutations，so as to provide reference for the stratified diagnosis and individualized treatment of PCa.
